NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) traded down 0.9% during mid-day trading on Tuesday . The company traded as low as $0.95 and last traded at $0.97. 56,197 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 239,378 shares. The stock had previously closed at $0.98.

NeuroSense Therapeutics Stock Down 0.9 %

The company has a market capitalization of $13.26 million, a price-to-earnings ratio of -1.52 and a beta of 1.36. The stock’s fifty day moving average price is $1.04 and its 200-day moving average price is $1.10.

NeuroSense Therapeutics (NASDAQ:NRSN) last issued its earnings results on Monday, April 7th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06.

Hedge Funds Weigh In On NeuroSense Therapeutics

A hedge fund recently bought a new stake in NeuroSense Therapeutics stock. Jane Street Group LLC bought a new position in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 64,636 shares of the company’s stock, valued at approximately $78,000. Jane Street Group LLC owned about 0.47% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.